Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis
Androgen receptor targeted therapies have emerged as an effective tool to manage advanced prostate cancer (PCa). Nevertheless, frequent occurrence of therapy resistance represents a major challenge in the clin...
The study couldn't prove cause and effect, but it found that statins, taken alone or with metformin, did seem associated with an increase in survival.
FRIDAY, Feb. 14, 2020 -- Drugs that many men with prostate cancer might already be taking -- cholesterol-lowering statins -- may help extend their survival if they have a " high-risk " form of the disease, new research suggests. High-risk patients...
Title: Cholesterol Drugs Might Help Curb 'High-Risk' Prostate CancersCategory: Health NewsCreated: 2/14/2020 12:00:00 AMLast Editorial Review: 2/14/2020 12:00:00 AM
ConclusionsStatin use alone or in combination with metformin was associated with lower all ‐cause and PCa mortality among high‐risk patients, particularly in post‐diagnostic settings; further studies are warranted.
(Thomas Jefferson University) Statin use alone or with metformin is associated with lower prostate cancer mortality from all causes, among high-risk patients.
Prostate Cancer and Prostatic Diseases, Published online: 06 February 2020; doi:10.1038/s41391-020-0207-5Associations among statins, preventive care, and prostate cancer mortality
Telephone intervention linked to rise in men ’s vegetable consumption but not to drop in risk of progression Related items fromOnMedica Less regular PSA screening puts men at risk NICE guidance delays hinder good diabetes care Population weight control best for cutting diabetes prevalence Starting statins not beneficial in many older adults NHS must hold CCGs accountable for poor diabetes care
ConclusionMetformin and statins were not associated with BFFS or DFFS improvement in our analysis. However, the small number of patients treated with these drugs limits the reliability of the results and prospective studies are needed.
Authors: Wang FM, Zhang Y Abstract Background: The effect of lipoprotein(a) (Lp(a)) on prostate cancer (PCa) is unclear. The aim of this study was to investigate the association between serum Lp(a) levels and clinicopathological features in patients with PCa. Methods: A total of 376 consecutive pathologically diagnosed PCa patients were enrolled and were classified as a low-intermediate-risk group or a high-risk group. The association of Lp(a) and the other lipid parameters including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides ...